Insights

Why the Rhythm (ASX:RHY) share price again reached a new all-time record today

The Rhythm Biosciences Ltd (ASX: RHY) has risen to another all-time high record following the update on the initial manufacturing of ColoSTAT.
The post Why the Rhythm (ASX:RHY) share price again reached a new all-time record today appeared first on The Motley Fool Australia. –

hand on touch screen lit up by a share price chart moving higher

It seems like Rhythm Biosciences Ltd (ASX: RHY) can do no wrong by investors at the moment. Today, the company’s shares have risen to another all-time high record following the update on the initial manufacturing of ColoSTAT.

During early morning trade, the Rhythm share price rose to an intraday high of $1.38. However, some profit taking have led its share to slightly retreat to, at the time of writing, $1.35, up 7.14%.

What’s driving the Rhythm share price to new highs?

The Rhythm share price is breaking new highs as investors are fighting to get a hold of its shares.

In its announcement, Rhythm advised that its global manufacturer, Biotem, has completed initial ColoSTAT prototype test kits. The small-scale production of ColoSTAT devices commenced in December, with delivery fulfilled ahead of schedule later that month.

Having received the first prototype units, Rhythm began testing the performance of ColoSTAT test kits with cancerous and healthy blood samples. The company noted that full testing is underway and will form Study 6, due to be completed by March 2021.

Rhythm noted that early quality assurance and performance test work is consistent with its own prototype test results.

Room for improvement

In addition to the assembly of ColoSTAT, the company stated that it has continued its efforts in advancing the technology behind the test kit. The current version, which is considered far superior than the current market standard faecal test, is undergoing improvements.

Rhythm advised it has allocated extra resources to its algorithm and software development division to enhance the existing technology on offer. As more samples arrive, it will use this to create a larger dataset to assess any performance changes made. New developments will be applied to study 7 and onward.

CEO commentary

Rhythm CEO, Mr Glenn Gilbert, hailed the milestone achievement, saying:

The objective of design transfer of the core ColoSTAT technology to our global manufacturer, Biotem, is to demonstrate that they are able to produce, in a commercial setting, the same consistent and high performing ColoSTAT test kit that Rhythm had achieved in lab.

The early view on the performance of the test kits manufactured by Biotem provides further confidence on our underlying technology that will drive the success of ColoSTAT into the future.

Where to invest $1,000 right now

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.

See The 5 Stocks

*Returns as of June 30th

More reading

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post Why the Rhythm (ASX:RHY) share price again reached a new all-time record today appeared first on The Motley Fool Australia.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;


To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.


An active and funded account with a positive trading balance is required to continue to have access to the tools;


Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;


Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!